NBTXR3 | Nano Publications

2019 – ESTRO – NBTXR3 activated by SBRT in liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

Patients with hepatocellular carcinoma (HCC) and liver metastasis (mets) present with a wide range of underlying liver dysfunctions and concomitant malignancies. Stereotactic body radiation therapy (SBRT) is well-tolerated and a valuable alternative for patients who are not eligible for invasive procedures. Yet, like all radiation therapy (RT) techniques, the energy dose deposit to tumor cells is limited by the surrounding healthy tissues. […]

Continuer la lecture…

2019 – ASCO-SITC – NBTXR3 with anti-PD-1 in advanced HNSCC or NSCLC

Abstracts, Donnée clinique de NBTXR3, Poumon, Tête & Cou

Despite proven efficacy, a limited number of patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or metastatic non-small cell lung cancer (NSCLC) benefit from anti-PD-1 treatment. Indeed, most pts do not respond to initial therapy due to intrinsic re-sistance to checkpoint inhibition. There is thus an important unmet medical need for a curative treatment in these pts and converting the local immune microenvironment to a “hot” phenotype may help to overcome therapeutic resistance. […]

Continuer la lecture…

2019 – ICHNO – Phase I/II NBTXR3 in HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Hafnium oxide nanoparticles, NBTXR3, were developed to augment tumor-localized high energy deposit once activated by ionizing radiation such as Intensity Modulated Radiation Therapy (IMRT) and thus to increase tumor cell death compared to the same dose of radiation. NBTXR3 is characterized by a single intratumoral (IT) administration and fits into standard radiotherapy schedule with no change in patient’s care pathway, treatment protocol or equipment. […]

Continuer la lecture…

2019 – ASCO GI – Phase I/II NBTXR3 in HCC and Liver Metastasis

Abstracts, Donnée clinique de NBTXR3, Foie

Compared to younger individuals, elderly patients with head and neck squamous cell carcinoma (HNSCC) have limited therapeutic options. Despite representing approximately 47% of the affected population with an increasing incidence, older patients are underrepresented from HNSCC prospective clinical trials further limiting their therapeutic options. […]

Continuer la lecture…

2018 – ASTRO – NBTXR3 Anti-Tumor Immune Response

Abstracts, Donnée clinique de NBTXR3, STM

Soft tissue sarcoma (STS) is a rare type of cancer, which occurs in tissues connecting, supporting and/or surrounding other structures of the body, like muscle, fat, etc. More than 50 subtypes of STS exist, characterized by a strong propensity to local recurrence and metastatic spreading. Consistently, the immune microenvironment in sarcomas is highly variable. A new class of high electron density material, hafnium oxide, was designed at the nanoscale to efficiently absorb ionizing radiation from within the tumor cells and increase the dose deposition into the tumor. […]

Continuer la lecture…

2019 – Bulletin Cancer – NBTXR3 improves pathological response

Divers, Divers, NO-RIGHTS, NO-RIGHTS, Publications, Publications

Doubling complete histological response in sarcomas with radiation therapy using nanoparticles (Hafnium oxide, NBTXR3), a phase III trial.

Continuer la lecture…

2018 – OncoRad – NBXTR3 in HNSCC and NSCLC with anti-PD1

Abstracts, Donnée clinique de NBTXR3, Poumon, Tête & Cou

Recent clinical studies have demonstrated the efficacy of anti-PD-1 in recurrent/metastatic HNSCC and upfront metastatic NSCLC patients. However, most patients with recurrent/metastatic HNSCC demon-strate innate (primary) resistance to checkpoint inhibition and do not respond to initial therapy and only a subset of metastatic HNSCC/NSCLC patients benefits from this treatment. […]

Continuer la lecture…

2018 – SIOG – NBTXR3 In Elderly With HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Continuer la lecture…

2018 – ASTRO – NBTXR3 Exploratory Dosimetric Study

Abstracts, Donnée clinique de NBTXR3, STM

NBTXR3, injectable hafnium oxide nanoparticles, was designed to increase the energy deposit of the irradiation when activated by radiotherapy for the treatment of solid tumors. It is currently evaluated in a phase II/III clinical trial in soft tissue sarcoma (STS) [NCT02379845] of the extremity and trunk wall, to compare its efficacy when intratumorally injected and activated by radiotherapy versus radiotherapy alone. […]

Continuer la lecture…

2018 – ASTRO – NBTXR3 in solid tumors

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

To improve radiotherapy (RT) in terms of tumor response and to reduce irradiation of healthy tissues, innovative therapeutic approaches are needed. In response, NBTXR3, injectable hafnium oxide nanoparticles, was developed for the treatment of solid tumors. Once injected intratumorally, NBTXR3 can deposit high energy within tumors only when activated by an ionizing radiation source, like current standard RTs. […]

Continuer la lecture…